Eikon Therapeutics, Inc. (EIKN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$5.69

From 52W high−60.70%

Volume658146.00

Market cap$346.11M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$5.69

From 52W high

−60.70%

Volume

658146.00

Market cap

$346.11M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

31.6

MomentumView details →

1D Return

+15.14%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−69.06%

ROA (TTM)

−41.33%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+15.14%

YTD Return

—

1Y Return

—

RSI (14)

31.6

vs 50D SMA

−34.32%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.54x

Current Ratio

9.89x

Quick Ratio

9.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.63

EPS Surprise

−3.16%

Beats (12Q)

0/12

Next Q EPS Est

−$1.82

Avg Surprise (4Q)

−28.46%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−322.16M

Op. CF (TTM)

−256.02M

Next earningsNov 12, 2026 →

Latest newsMore news →

Eikon Therapeutics, Inc. presented updated EIK1001 data from the TeLuRide-005 study at the 2026 ESMO Congress.10d ago

Eikon Therapeutics, Inc. announced that seven abstracts covering its clinical candidates were published for presentation at the 2026 ESMO Congress beginning October 23 in Madrid.17d ago

Similar companies

Galectin Therapeutics Inc.GALT Alector, Inc.ALEC AgomAb Therapeutics N.V. American Depositary SharesAGMB Opus Genetics, Inc.IRD Atea Pharmaceuticals, Inc.AVIR Orchestra BioMed Holdings, Inc.OBIO Find similar companies →

Latest newsMore news →

Eikon Therapeutics, Inc. presented updated EIK1001 data from the TeLuRide-005 study at the 2026 ESMO Congress.10d ago Eikon Therapeutics, Inc. announced that seven abstracts covering its clinical candidates were published for presentation at the 2026 ESMO Congress beginning October 23 in Madrid.17d ago Eikon Therapeutics, Inc. submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate EIK1006 for advanced metastatic prostate cancer.21d ago